Actively Recruiting
Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-03-18
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to establish a population of patients with Lyme disease for evaluation, treatment and follow-up to learn more about the infection. Patients with active Lyme disease may be eligible for this study. Participants will have a medical history and physical examination and diagnostic evaluations as appropriate to their individual condition. Laboratory tests may include routing blood and urine tests, X-rays, or other imaging studies, body fluid or tissue cultures, skin biopsy and tests for allergic or immune responses. Treatment will include only medications approved by the Food and Drug Administration, given according to accepted dose schedules and ways of taking the medicines. All diagnostic tests and treatments will be according to standard medical practice for the disease. No experimental procedures will be offered under this protocol. Patients will be followed as needed for evaluation and treatment of their condition. In general, they will be asked to return at the end of therapy, then 3, 6 and 12 months later, and then every 6 to 12 months. More frequent visits may be required or less frequent visits may be allowed, depending on the individual s condition. Participants may be asked to undergo the following additional procedures for research purposes: * Extra blood draws to study Lyme disease and other inflammatory conditions. Blood will be drawn from arm veins. The total amount drawn during any 6-week period will not exceed 450 cc (30 tablespoons) for adults and 7 cc (1/2 tablespoon) per kilogram (2.2 pounds) of body weight for children under 18 years of age. * Leukapheresis to collect large numbers of white blood cells. Whole blood is collected through a needle in an arm vein, similar to donating blood. The blood circulates through a machine that separates it into its components, and the white cells are removed. The rest of the blood is returned to the body through the same needle. Only adults 18 years of age and older will be asked to undergo leukapheresis.
CONDITIONS
Official Title
Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of active Lyme disease at the time of initial NIH evaluation based on CDC case definition
- Study physician will confirm probable cases
- Subjects must maintain a private physician for non-study related medical issues and emergencies
You will not qualify if you...
- Post treatment Lyme disease syndrome
- Poor compliance that would interfere with study or medical care
- For apheresis: under 18 years old or weight 110 pounds or less
- Known heart, lung, kidney disease, or bleeding disorders (for apheresis)
- Positive HIV, HCV, or HBsAg tests (for apheresis)
- Pregnant or nursing females (for apheresis)
- Hemoglobin below 11 g/dL for males or below 10 g/dL for females (for apheresis)
- Platelets below 150 k/mm3 (for apheresis)
- White blood cells below 3.5 x 10^3/uL (for apheresis)
- MCV below 80 (for apheresis)
- Women able to conceive must have a negative pregnancy test within 2 weeks before apheresis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
A
Ashley M Thomas
CONTACT
A
Adriana R Marques, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here